Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 4
2004 13
2005 7
2006 6
2007 2
2008 6
2009 8
2010 5
2011 12
2012 10
2013 21
2014 15
2015 15
2016 19
2017 18
2018 15
2019 29
2020 17
2021 28
2022 30
2023 16
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Results by year

Filters applied: . Clear all
Page 1
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA; FOENIX-CCA2 Study Investigators. Goyal L, et al. Among authors: chen lt. N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834. N Engl J Med. 2023. PMID: 36652354 Clinical Trial.
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Kang YK, et al. Among authors: chen lt. Lancet Oncol. 2022 Feb;23(2):234-247. doi: 10.1016/S1470-2045(21)00692-6. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030335 Clinical Trial.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Wang-Gillam A, et al. Among authors: chen lt. Lancet. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Lancet. 2016. PMID: 26615328 Clinical Trial.
Foreword.
Rocha F, Chen LT. Rocha F, et al. Among authors: chen lt. Hepatobiliary Surg Nutr. 2019 Mar;8(Suppl 1):S1. doi: 10.21037/hbsn.2019.02.12. Hepatobiliary Surg Nutr. 2019. PMID: 30997361 Free PMC article. No abstract available.
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Kang YK, et al. Among authors: chen lt. Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6. Lancet. 2017. PMID: 28993052 Clinical Trial.
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Lee MA, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, Żotkiewicz M, Kurland JF, Cohen G, Valle JW. Oh DY, et al. Among authors: chen lt. Future Oncol. 2023 Nov;19(34):2277-2289. doi: 10.2217/fon-2023-0468. Epub 2023 Sep 25. Future Oncol. 2023. PMID: 37746835 Free article. Review.
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N. Chen LT, et al. Gastric Cancer. 2020 May;23(3):510-519. doi: 10.1007/s10120-019-01034-7. Epub 2019 Dec 20. Gastric Cancer. 2020. PMID: 31863227 Free PMC article. Clinical Trial.
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Ah Lee M, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, He P, Kurland JF, Cohen G, Valle JW. Oh DY, et al. Among authors: chen lt. NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1. NEJM Evid. 2022. PMID: 38319896
Epigenetic regulation in the carcinogenesis of cholangiocarcinoma.
Chiang NJ, Shan YS, Hung WC, Chen LT. Chiang NJ, et al. Among authors: chen lt. Int J Biochem Cell Biol. 2015 Oct;67:110-4. doi: 10.1016/j.biocel.2015.06.012. Epub 2015 Jun 19. Int J Biochem Cell Biol. 2015. PMID: 26100596 Review.
265 results